产品中心您的位置:网站首页 > 产品中心 > 生物试剂 > 其他生化试剂 > 1144068-46-1WYE-125132 (WYE-132)1144068-46-1

WYE-125132 (WYE-132)1144068-46-1

更新时间:2024-05-25

访问量:531

厂商性质:经销商

生产地址:上海一基

简要描述:
WYE-125132 (WYE-132)1144068-46-1
上海一基实业有限公司是主要从事配套试剂的生产和销售的企业,产品用途:科研实验,标准对照品研究中心代理的作为一种衡量标准

WYE-125132 (WYE-132)1144068-46-1

WYE125132 (WYE-132)
分子式:C27H33N7O4   分子量:519.6
 
产品描述
WYE-125132 是高度有效的,ATP竞争性的,mTOR抑制剂,IC50为0.19 nM;作用于mTOR比作用于PI3Ks或PI3K相关激酶hSMG1和ATR选择性高。
靶点
mTOR
         
IC50
0.19 nM
         
体外研究
WYE-125132 potently and ATP-competitively inhibits recombinant mTOR kinase with IC50 of 0.19 nM and also shows the high selectivity over various PI3Ks and a panel of 230 protein kinases.In vitro, WYE-125132 exhibits a significant anti-proliferative activity against a panel of tumor cell lines with IC50 ranging from 2 nM (LNCap) to 380 nM (HTC116). Besides, WYE-125132 also causes cell cycle progression, induction of apoptosis, and inhibition of protein synthesis and cell size.WYE-125132 results in a significant reduction in the synthesis of pre-tRNALeu by 72%, 80%, and 53% in actively proliferating cells of MG63, MDA361, and HEK293, respectively by inhibiting mTORC1. Moreover, WYE-125132 is also found to induce the dephosphorylation of Maf1 (negative regulator of Pol III transcription) and its accumulation in the nucleus.
体内研究
WYE-125132 (5 mg/kg p.o.) produces significant antitumor activity and causes dose-dependent tumor growth delay in the PI3K/mTOR- and HER2-hyperactive MDA361 tumor model. In addition, WYE-125132 also shows potent antitumor efficacy in the PTEN-null glioma U87MG, non-small cell lung cancer H1975 and A549 models.
溶解性
DMSO 104 mg/mL,水 <1 mg/mL,乙醇 <1 mg/mL
稳定性
2年 -20°C粉状,6月-80°C溶于DMSO
特征
WYE-125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor.

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7